Why the study?
With vaccines in development, population-based estimates of norovirus burden are needed to identify target populations, quantify potential benefits, and understand disease dynamics.
What is the attributable fraction of acute gastroenteritis episodes and ED visits to norovirus genogroups I and II in children?
What is the attributable fraction of acute gastroenteritis episodes and ED visits to norovirus genogroups I and II in children?
A large proportion of norovirus GII detections in children reflect causation, highlighting the significant potential benefit of norovirus GII vaccines.
Answers are grounded in this paper and cite their sources.
May inform pediatric norovirus vaccine targeting; leaves open validation in prospective cohorts.
BACKGROUND: Norovirus is a leading cause of acute gastroenteritis. With vaccines in development, population-based estimates of norovirus burden are needed to identify target populations, quantify potential benefits, and understand disease dynamics. METHODS: We estimated the attributable fraction (AF) for norovirus infections in children, defined as the proportion of children testing positive for norovirus whose gastroenteritis was attributable to norovirus. We calculated the standardized incidence and emergency department (ED) visit rates attributable to norovirus using provincial gastroenteritis visit administrative data. RESULTS: From 3731 gastroenteritis case patients and 2135 controls we determined that the AFs were 67.0% (95% confidence interval [CI], 31.5%-100%) and 91.6% (88.8%-94.4%) for norovirus genogroups I (GI) and II (GII), respectively. Norovirus GII AF varied by season but not age. We attributed 116 episodes (95% CI, 103-129) and 59 (51-67) ED visits per 10 000 child-years to norovirus GII across all ages, accounting for 20% and 18% of all medically attended gastroenteritis episodes and ED visits, respectively. CONCLUSIONS: In children, a large proportion of norovirus GII detections reflect causation, demonstrating significant potential for norovirus GII vaccines. Seasonal variation in the norovirus GII AF may have implications for understanding the role asymptomatic carriage plays in disease dynamics.
No takes yet. Share an insight, caveat, or question.
Tarr et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: